Compare · EMIS vs NVO
EMIS vs NVO
Side-by-side comparison of Emmis Acquisition Corp. (EMIS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EMIS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $187.53B.
- Over the past year, EMIS is up 1.8% and NVO is down 38.9% - EMIS leads by 40.7 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 1 for EMIS).
- NVO has more recent analyst coverage (25 ratings vs 0 for EMIS).
- Company
- Emmis Acquisition Corp.
- Novo Nordisk A/S
- Price
- $10.12+0.40%
- $44.01+4.76%
- Market cap
- -
- $187.53B
- 1M return
- +0.00%
- -1.97%
- 1Y return
- +1.81%
- -38.90%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 1
- 11
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EMIS
- SEC Form 10-Q filed by Emmis Acquisition Corp.
- SEC Form 10-K filed by Emmis Acquisition Corp.
- Amendment: SEC Form SCHEDULE 13G/A filed by Emmis Acquisition Corp.
- SEC Form SCHEDULE 13G filed by Emmis Acquisition Corp.
- Amendment: SEC Form SCHEDULE 13G/A filed by Emmis Acquisition Corp.
- Amendment: SEC Form SCHEDULE 13G/A filed by Emmis Acquisition Corp.
- Sichenzia Ross Ference Carmel LLP Achieves Firm Record Advising on Over 170 Transactions Totaling Over $14 Billion in 2025
- SEC Form SCHEDULE 13G filed by Emmis Acquisition Corp.
- SEC Form 10-Q filed by Emmis Acquisition Corp.
- SEC Form SCHEDULE 13G filed by Emmis Acquisition Corp.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates